Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on community preparedness for anaphylaxis following new MHRA-approved adrenaline delivery formats with different usability and stability characteristics.

Officials at the Department, in discussion with the Medicines and Healthcare products Regulatory Agency, are in the early stages of considering if potential amendments to Schedule 17 of the Human Medicines Regulations (HMRs) 2012 are required to reflect the availability of new adrenaline delivery technologies.

No specific assessment has been made of the potential impact on community preparedness for anaphylaxis. However, should amendments to the HMRs be required, then the Government will conduct a public consultation to ensure that the views of stakeholders are carefully considered, prior to any changes being made.

If changes are made to the HMRs, all relevant guidance will be updated to reflect this change.